Presentation av Qlife på Stora Aktiedagen

2019-11-06 10:20

Presentation av Qlife på Stora Aktiedagen

VD Thomas Warthoe kommer att presentera Qlife på Stora Aktiedagen i Göteborg den 4/11 och Stockholm den 25/11. Vill ni läsa mer om dagarnas hela program och anmälan, se bifogad anmälan.

2026-01-22 20:50

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

2026-01-19 08:30

Qlife prepares for pharmacy testing in Nordic markets

2026-01-15 08:30

Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

2025-12-23 08:30

Qlife provides end-year operational update on key issues

2025-12-16 08:31

Qlife and Hipro sign exclusive commercial agreement covering Qlife’s sale of Hipro products in EU and US markets

2025-12-16 08:30

The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

2025-12-12 08:30

Egoo Health powers AI-driven personalized diabetes management in China

2025-12-05 11:13

Qlife’s Birmingham PKU clinical trial published with strong results – key milestone toward CE-mark submission and market launch

2025-11-14 17:37

Update on the reverse takeover process – “Red Chip” structure will not be approved by Nasdaq – other structures are pursued